Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Romanel

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|May 30, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Minari, Daniele Cretella, et al.
Molecular Oncology|May 23, 2025
TRPM8 levels determine tumor vulnerability to channel agonistsAlessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, et al.
NPJ Genomic Medicine|August 8, 2017
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer careHanna Rennert, Kenneth Eng, Tuo Zhang, et al.
JTO Clinical and Research Reports|February 24, 2022
<i>YES1</i> and <i>MYC</i> Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical ProofsRoberta Minari, Samuel Valentini, Denise Madeddu, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
NAR Cancer|June 6, 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayFrancesco Orlando, Alessandro Romanel, Blanca Trujillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2018
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate CancerDaniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, et al.
The Journal of Clinical Investigation|February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerHimisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
Science Advances|March 15, 2024
Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of <i>Arid1a</i> mutationsAlessandro D'Ambrosio, Davide Bressan, Elisa Ferracci, et al.
EMBO Reports|December 5, 2024
Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancerDario De Felice, Alessandro Alaimo, Davide Bressan, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Journal of Experimental & Clinical Cancer Research : CR|May 30, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Minari, Daniele Cretella, et al.
Molecular Oncology|May 23, 2025
TRPM8 levels determine tumor vulnerability to channel agonistsAlessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, et al.
NPJ Genomic Medicine|August 8, 2017
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer careHanna Rennert, Kenneth Eng, Tuo Zhang, et al.
JTO Clinical and Research Reports|February 24, 2022
<i>YES1</i> and <i>MYC</i> Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical ProofsRoberta Minari, Samuel Valentini, Denise Madeddu, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
NAR Cancer|June 6, 2022
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assayFrancesco Orlando, Alessandro Romanel, Blanca Trujillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2018
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate CancerDaniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, et al.
The Journal of Clinical Investigation|February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerHimisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
Science Advances|March 15, 2024
Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of <i>Arid1a</i> mutationsAlessandro D'Ambrosio, Davide Bressan, Elisa Ferracci, et al.
EMBO Reports|December 5, 2024
Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancerDario De Felice, Alessandro Alaimo, Davide Bressan, et al.
Pageof 7